KLC2 (kinesin light chain 2) is a light chain component of kinesin-1 that mediates cargo binding and regulates kinesin-1 motility for microtubule-based transport. KLC2 recruits kinesin-1 to lysosomes through binding with PLEKHM2 and ARL8B, directing lysosomal movement toward microtubule plus ends 1. In cochlear hair cells, KLC2 is essential for proper mitochondrial transport and GABAA receptor regulation; KLC2 deficiency causes low-frequency sensorineural hearing loss in mice and humans, reversible by gene therapy 2. Beyond auditory function, KLC2 contributes to cancer progression. In hepatocellular carcinoma, the LINC00152-miR-143a-3p-KLC2 axis promotes cell proliferation and migration, with high KLC2 expression associated with poor survival 3. In non-small cell lung cancer, KLC2 suppresses p53 phosphorylation through a positive feedback loop with HuR mRNA-binding protein, promoting radioresistance 4. In chr11 myeloid leukemia, KLC2 mutations enhance BCR::ABL1-driven leukemogenesis and reduce tyrosine kinase inhibitor sensitivity through STAT3 activation 5. KLC2 also interacts with developmental proteins like MAB21L2 in eye development 6. These findings establish KLC2 as a multifunctional transport protein with critical roles in both normal cellular homeostasis and disease pathogenesis.